Press

PressMarch 8, 2021

MindMed Announces C$19.5 Million Bought Deal Private Placement Offering

PressMarch 5, 2021

Silo Wellness Commences Trading on the Canadian Securities Exchange

PressMarch 4, 2021

Psyence Group Launches its Functional Mushroom Brand, “Goodmind”

PressMarch 3, 2021

Cybin Inc. Announces Uplisting to OTCQB Venture Market

PressMarch 3, 2021

atai Life Sciences Announces $157 Million Series D Financing Round

PressMarch 2, 2021

TheraPsil Launches Beta Version of Psilocybin Therapy Training Program

PressMarch 1, 2021

MindMed Closes Acquisition of HealthMode

PressFebruary 26, 2021

PsyBio Therapeutics Corp. Begins Trading on the TSX Venture Exchange

PressFebruary 25, 2021

PharmaDrug Files For FDA Orphan Drug Designation For DMT

PressFebruary 24, 2021

NeonMind Purchases Synthetic Psilocybin from Psygen Labs

PressFebruary 23, 2021

PharmaTher Announces Research Collaboration for Microneedle Delivery of Psychedelic Pharmaceuticals

PressFebruary 22, 2021

Awakn Announces Results of the World’s First ‘MDMA in Alcohol Use Disorder’ Trial

PressFebruary 19, 2021

Mindset Pharma Added to North American Psychedelics Index

PressFebruary 18, 2021

Revive Therapeutics Acquires Unique Psilocybin Assets

PressFebruary 17, 2021

MindMed’s LSD Neutralizer Study Begins

PressFebruary 15, 2021

Mydecine Innovations Group Closes $17,250,000 Bought-Deal Public Offering

PressFebruary 12, 2021

PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke

PressFebruary 11, 2021

MindMed Signs Partnership with MindShift Compounds AG

PressFebruary 10, 2021

XPhyto Adds Mescaline Production to Psychedelic Medicine Programs

PressFebruary 9, 2021

PharmaDrug Appoints DMT Expert

PressFebruary 9, 2021

Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller

PressFebruary 8, 2021

Bright Minds Biosciences Announces Listing on Canadian Stock Exchange

PressFebruary 5, 2021

Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds

PressFebruary 4, 2021

Dr. Robin Carhart-Harris joins Osmind as a Scientific Advisor